In Case You Missed It: GlaxoSmithKline Just Had a Phenomenal Week!
Sean Williams, The Motley Fool - Motley Fool - 41 mins ago
It may have been a holiday-shortened week, but global pharmaceutical giant GlaxoSmithKline packed quite the punch with four positive news events bound to excite even the most skeptical Glaxo shareholders. Of course, Glaxo's week was also marred...
Theravance to Report First Quarter 2014 Financial Results on May 6, 2014
Marketwire - Tue Apr 15, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended March 31, 2014 after market close on Tuesday, May 6, 2014.
Theravance Set to Possibly Rebound After Yesterday's Selloff of 2.86%
Comtex SmarTrend(R) - Mon Apr 14, 5:54PM CDT
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $26.71 to a high of $28.77. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $27.34 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Theravance Shares Down 19.2% Since SmarTrend's Sell Call (THRX)
Comtex SmarTrend(R) - Thu Apr 10, 5:08PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 1 month, Theravance has returned 19.16% as of today's recent price of $28.01.
Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD
Marketwire - Thu Apr 10, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) announced the initiation of the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD). TD-4208 is an investigational inhaled long-acting muscarinic antagonist (LAMA), discovered using Theravance's multivalent approach to drug design.
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
Downtrend Call Working As Theravance Stock Falls 13.9% (THRX)
Comtex SmarTrend(R) - Thu Apr 03, 11:20AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 4 weeks, Theravance has returned 13.94% as of today's recent price of $29.82.
Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Theravance Appoints Kevin Kwok, Head of Talent Acquisition and Strategy
Marketwire - Tue Apr 01, 3:05PM CDT
Theravance, Inc. (the "Company"
Is There A Good Explanation For Higher Returns In Women-run Funds?
at The Street - Mon Mar 31, 5:42PM CDT
James Dennin, Kapitall: Women-run funds outperformed last year. Is there a good explanation for this or are women just better?a���� This [...]
Big Pharma's Not-So-Hidden Secret to Success
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 11:05AM CDT
The past week may have been a bit of a bumpy ride for the pharmaceutical and biotech sector following congressional testimony that highlighted the rising cost of branded drugs, but it represents nothing more than a tiny hurdle in what's been an...
Theravance to Present at the 13th Annual Needham Healthcare Conference
Marketwire - Wed Mar 26, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 9:20 a.m. EDT. The conference will be held from April 8-9, 2014 at The Westin New York Grand Central Hotel, New York, NY.
1 More Promising Asthma Drug by GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 19, 5:30PM CDT
No one has a bigger presence in asthma than GlaxoSmithKline . The company's Advair, a treatment for chronic asthma, generated over $4 billion in sales in the U.S. and more than $8 billion world wide last year. Advair is the best selling drug in...
Glaxo/Theravance Update on COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 5:30PM CDT
GlaxoSmithKline and partner Theravance announced encouraging data from three phase III studies on Anoro Ellipta.
Update on Glaxo's Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 12:53PM CDT
GlaxoSmithKline announced positive data from two phase III studies on mepolizumab.
GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
Marketwire - Fri Mar 14, 7:01AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies. Two studies comparing the efficacy and safety of the combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro(TM) Ellipta(TM) (umeclidinium/vilanterol, 'UMEC/VI'
Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
Marketwire - Thu Mar 13, 7:02AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar(R)/Breo(R) Ellipta(R) (fluticasone furoate 'FF'/vilanterol 'VI'
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Theravance to Split in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 11:00AM CST
Theravance will split into two independent companies in the second quarter.